Transformative Exosome Therapeutics
Evox Therapeutics is harnessing and engineering the natural delivery capabilities of extracellular vesicles to develop an entirely novel class of biotherapeutics.
By combining groundbreaking exosome technology from well-renowned Oxford University and the Karolinska Institute - the home of the Nobel Prize – we aim to revolutionise the treatment of a broad range of severe diseases, with profound implications for human health.
Evox Therapeutics has built a comprehensive intellectual property portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas, using an equally wide array of therapeutic modalities.